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Objectives We conducted a randomized trial to assess the effectiveness of F-18-fluorodeoxyglucose (FDG) positron emission tomogra-
phy (PET)-assisted management in patients with severe ventricular dysfunction and suspected coronary disease.
Background Such patients may benefit from revascularization, but have significant perioperative morbidity and mortality.
F-18-fluorodeoxyglucose PET can detect viable myocardium that might recover after revascularization.
Methods Included were patients with severe left ventricular (LV) dysfunction and suspected coronary disease being consid-
ered for revascularization, heart failure, or transplantation work-ups or in whom PET was considered potentially
useful. Patients were stratified according to recent angiography or not, then randomized to management as-
sisted by FDG PET (n  218) or standard care (n  212). The primary outcome was the composite of cardiac
death, myocardial infarction, or recurrent hospital stay for cardiac cause, within 1 year.
Results At 1 year, the cumulative proportion of patients who had experienced the composite event was 30% (PET arm)
versus 36% (standard arm) (relative risk 0.82, 95% confidence interval [CI] 0.59 to 1.14; p  0.16). The hazard
ratio (HR) for the composite outcome, PET versus standard care, was 0.78 (95% CI 0.58 to 1.1; p 0.15); for patients
that adhered to PET recommendations for revascularization, revascularization work-up, or neither, HR 0.62 (95% CI 0.42
to 0.93; p 0.019); in those without recent angiography, for cardiac death, HR 0.4 (95% CI 0.17 to 0.96; p 0.035).
Conclusions This study did not demonstrate a significant reduction in cardiac events in patients with LV dysfunction and sus-
pected coronary disease for FDG PET-assisted management versus standard care. In those who adhered to PET
recommendations and in patients without recent angiography, significant benefits were observed. The utility
of FDG PET is best realized in this subpopulation and when adherence to recommendations can be achieved.
(J Am Coll Cardiol 2007;50:2002–12) © 2007 by the American College of Cardiology Foundation
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November 13, 2007:2002–12 FDG PET-Assisted Management (The PARR-2 Study)evere left ventricular (LV) dysfunction due to coronary
rtery disease (CAD) is associated with high morbidity and
ortality despite advances in medical and device therapies
1–6). Heart failure, a frequent complication of this condi-
ion, is also associated with significant health care costs (4).
lthough revascularization might be beneficial, periopera-
ive morbidity and mortality often temper the enthusiasm to
perate on such patients (7–9). Undoubtedly, these patients
ave much to gain when revascularization is beneficial but also
uch to lose when it is not helpful. For this reason, methods
ave been developed to define viable recoverable myocardium.
Positron emission tomography (PET) imaging with
-18-fluorodeoxyglucose (FDG) is considered the most
ensitive viability imaging method for predicting LV func-
ion recovery (10–13). Several observational studies have
hown that FDG PET can identify patients with viable
yocardium who are at high risk for cardiac events if they
o not undergo timely revascularization (14–20). However,
ecause of their design, these studies could not determine
hether clinical decisions assisted by FDG PET imaging
ctually altered patient outcome.
See page 2013
The primary objective of this study was to determine
hether patients whose management strategy included
DG PET imaging to assist in decision-making, had
mproved clinical outcomes compared with standard care
here FDG PET was not available. In our experience,
any patients are referred for viability imaging without
ecent knowledge of their coronary anatomy. As such, a
econdary aim was to determine whether patients with or
ithout recent coronary angiography gained a clinical ben-
fit from management assisted by FDG PET imaging.
ethods
etails of the enrollment criteria and protocol are summa-
ized in the following text. Full comprehensive details of the
ethods and design have been published separately (21).
Patients from 9 centers were enrolled between June 2000
nd September 2004. The study was approved by the
nstitutional review board at each site, and all patients
nrolled gave written informed consent.
atients. Candidates for enrollment were patients being
onsidered for: 1) revascularization or revascularization
ork-up; 2) transplantation work-up; or 3) heart failure
ork-up; or 4) any patient for whom FDG PET viability
maging might be considered useful by the attending phy-
ician for decision-making and who met other inclusion
riteria. Patients were identified from heart failure clinics,
ardiology inpatients, cardiac catheterization laboratories,
urgical referral rounds, and nuclear cardiology viability
maging referrals. Eligible patients were included if they
ere over 18 years of age; had an ejection fraction (EF)
35% documented by radionuclide ventriculography aRVG), LV angiogram, or echo-
ardiography; had a high suspi-
ion of CAD on the basis of one
r more of the following: coro-
ary angiography; previous re-
ascularization; previous myocar-
ial infarction (MI) (4 weeks)
erified by chart review; and/or
ositive stress perfusion imaging
or scar / ischemia (reports
ere reviewed by a cardiovascular
uclear imaging specialist). Ex-
luded were patients in whom a
efinite decision had already
een made for revascularization
r transplantation such that the
ttending physician would in no
ay alter management on the
asis of any potential viability
ndings; and those who had al-
eady had FDG viability imag-
ng. Also excluded were those:
ith comorbidities that would likely affect survival over the
tudy duration; 4 weeks post-MI; already identified to be
nsuitable for revascularization; requiring emergency revas-
ularization; with severe valvular disease that required sur-
ery; or who were geographically inaccessible.
maging. Patients underwent RVG imaging at baseline.
he RVGs were acquired with a standard electrocardiogram-
ated equilibrium technetium-99m red blood cell blood
ool imaging protocol. The EF was measured from the left
nterior oblique 45° acquisition (22).
Those randomized to the PET arm underwent imaging at 1
f 4 sites (see Appendix). The PET perfusion imaging was
cquired at rest with a standard protocol with rubidium-82 or
-13-ammonia as described previously (21–23). For FDG
maging, nondiabetic patients were studied after an oral glucose
oad (21–23), whereas an insulin-euglycemic clamp was used
or those with diabetes (21–24).
ET IMAGING DATA ANALYSIS AND INTERPRETATION. All
mages were submitted to the PET imaging core laboratory
or standardized processing. An automated method of
mage analysis was applied to the perfusion/FDG PET
maging data to yield quantified measures of the extent and
everity of scar and mismatch (Fig. 1). These parameters
ere included with clinical parameters in a previously
erived model that yielded a point estimate and 95%
onfidence interval (CI) for predicted LV function recovery
fter revascularization (21,22). Patients were classified as
aving low, moderate, or high likelihood of recovery if
dequate revascularization could be achieved (low classifi-
ation was considered when the upper confidence limit of
he predicted EF change was 3% or less; high classification
hen the lower confidence limit for predicted change was
Abbreviations
and Acronyms
CABG  coronary artery
bypass graft
CAD  coronary artery
disease
CI  confidence interval
EF  ejection fraction
FDG 
F-18-fluorodeoxyglucose
HR  hazard ratio
LV  left
ventricle/ventricular
MI  myocardial infarction
MRI  magnetic resonance
imaging
PET  positron emission
tomography
RVG  radionuclide
ventriculographybove 3%; and moderate for those with confidence limits
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FDG PET-Assisted Management (The PARR-2 Study) November 13, 2007:2002–12etween high and low cut-points). Physicians experienced
n reading PET data also reviewed the images to confirm
he model’s classification of the likelihood of recovery.
hysicians considered the extent of scar and mismatch in
heir interpretation. Differences between the model and the
nterpreting physician were settled by consensus with an-
ther experienced imaging physician. In addition to a
tandard clinical report describing the imaging findings, a
eport detailing the extent of scar (defined as small [16%],
edium [16% to 27%], or large [27%]) (21), the extent of
otal viable myocardium, the extent of mismatch (all as a
ercent of the LV), and the likelihood for recovery was
axed and delivered to the attending physician or surgeon
21). The physician or surgeon would then make a decision
hether to proceed with revascularization (or revasculariza-
ion work-up in those without recent angiography).
andomization and interventions. Block randomization
as performed. The randomization was pre-stratified by
hether the patient had had angiography within the pre-
eding 6 months and by the study center. Physicians and
taff were unaware of allocation before randomization.
asking was employed where feasible, including masking
f the allocation process, the outcomes using an adjudica-
ion process, and the interim analysis.
DG-PET–ASSISTED MANAGEMENT ARM. When FDG PET
dentified significant viable myocardium, “revascularization”
r “revascularization work-up” was recommended depend-
ng on whether or not the patient had recent angiography.
hen PET identified predominantly scar tissue, “no revas-
ularization” was the recommendation. When the PET
eport was available, the physician or surgeon would then
onsider the imaging data in the context of the individual
atient and make a decision to proceed or not proceed with
evascularization (or revascularization work-up in those
ithout recent angiography). In circumstances where the
car was large, aneurysm resection could be considered at
he physician’s and surgeon’s discretion.
TANDARD CARE ARM. Standard care proceeded without
DG imaging available to the physician. An alternative test
or viability definition could be considered.
We were aware that some patients could have “vessels
hich were unsuitable for revascularization.” Such patients
dentified before recruitment were excluded from enroll-
ent. Patients who were directed to undergo angiography
ut were subsequently considered to have “unsuitable anat-
my” continued to be followed in their respective arms on
n intention-to-treat basis.
For both arms, once initial testing and evaluation were
ompleted, the physician or surgeon would then consider
he imaging data in the context of the individual patient and
ake a decision to proceed or not with revascularization (or
evascularization work-up in those without recent angiog-
aphy). Every effort was made to ensure that all procedures
nd subsequent revascularizations were booked within 8Patient A 
Patient B
Scar Ma Mismatch ma
Mismatch Score = 18%Scar Score = 8%
Raw Perfusion
Normalized Perfusion Normalized FDG
Raw FDG
Raw FDG
Raw Perfusion 
Normalized FDGNormalized Perfusion 
Scar Ma Mismatch ma
Scar Score = 31% Mismatch Score = 3%
p p
pp
Figure 1 Examples of Reconstructed
Polar Maps for 2 Patients
In each set, the top panels are the raw perfusion (left) and raw F-18-fluorode-
oxyglucose (FDG) uptake (right) polar maps; the middle panels are the normal-
ized perfusion (left) and FDG uptake (right); the lowest panels are the scar
score (left) and mismatch score (right); color scale in the lower panel is
shifted to allow visualization of defects (this does not affect the score determi-
nations). (Patient A) Predominantly scar in the anteroseptal are inferolateral
walls and apex. Of the total left ventricular (LV) myocardium; 31% was scar and
3% was mismatch. Interpretation was that there was a large scar and a small
amount of hibernating viable myocardium and that the patient would not be
expected to improve after revascularization. (Patient B) Partial mismatch (mix-
ture of scar and hibernating myocardium) in the large defect involving the infe-
rior wall and apex and extending to the anteroseptal wall. Of the total LV
myocardium; 8% was scar and 18% was mismatch. The interpretation was that
there was a large amount of hibernating viable myocardium and that the
patient would be expected to improve after revascularization.eeks of randomization. The management plans were
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November 13, 2007:2002–12 FDG PET-Assisted Management (The PARR-2 Study)eviewed at 8 weeks after randomization. Revascularizations
irected by initial work-up (with or without PET) were
onsidered protocol revascularizations. Their associated
ospital stays were not counted as events.
ardiac event variable definitions and measurement. The
rimary event of interest was the occurrence of any of the
ollowing within 1 year of randomization: cardiac death, MI,
r hospital stay for cardiac cause such as unstable angina or
eart failure. Secondary outcomes included time to occurrence
f the composite event and time to cardiac death. Events were
ssessed by telephone interview every 3 months. All events
ere reviewed and verified by an adjudication committee
linded to the randomization allocation.
In our initial design, cardiac transplantation had been
ncluded in the composite end point (21). This was an
mportant event to capture for the planned cost analysis.
owever, we are aware that cardiac transplant can be
onsidered a positive rather than a negative outcome. Hence
or outcome analysis, patients with cardiac transplant were
ensored at the time of cardiac transplantation.
The definitions of each variable and the timing of their
easurements have been described previously and are sum-
arized in the following text (21).
Cause of death was determined from the death certificate
nd included death presumed to be tachyarrhythmic (i.e.,
brupt loss of cardiac output and pulse without prior
irculatory collapse and with no evidence of shock or
ulmonary edema at the time of loss of cardiac output) or
eath from other cardiac cause (i.e., 5 min or more of
irculatory collapse before loss of cardiac output and pulse
ith evidence of shock or severe pulmonary edema before
oss of cardiac output and subsequent death).
Myocardial infarction was defined as 2 or more of the
ollowing: ischemic chest pain lasting at least 20 min, accom-
anied by documentation in the medical record of new ST-
egment elevation 1 mm in at least 2 contiguous leads, new
eft bundle branch block, evolution of creatine kinase (CK) rise
2 normal or CK-myocardial band above upper limit of
ormal, or new Q waves in 2 contiguous leads.
Procedure-related MI was defined as the following: 1)
oronary artery bypass graft (CABG): an enzymatic MI
eflects cases with increased CK-myocardial band 70 or
roponin-T 1.5; clinical MI includes positive enzymes
lus 1 or more of the following: new Q waves, new lack of
-wave progression, or new wall motion abnormalities; 2)
ercutaneous coronary intervention: post-percutaneous cor-
nary intervention MI was based on the elevation of the
K-myocardial band 3 the upper limit of normal or by
he occurrence of new Q waves.
Cardiac hospital stay was defined as hospital stay for a
ardiac cause such as unstable angina, worsening heart
ailure, or non-protocol late revascularization.
Unstable angina was defined as anginal pain that occurred at
est and lasted at least 20 min or angina of at least Canadian
ardiovascular Society (CCS) class III with onset within 2
onths or that was distinctly more frequent, longer in dura- lion, or lower in threshold (i.e., increased at least 1 CCS class
ithin 2 months and was at least CCS class III in severity).
Worsening heart failure was defined as: change of func-
ional class (i.e., increased at least 1 New York Heart
ssociation functional class in the last 2 months); change in
linical examination findings (new S3, rales, elevated jugular
ein pressure not previously noted); required adjustment of
iuretic therapy; acute pulmonary edema; or cardiogenic
hock.
tatistical analysis. The sample size of 206 patients/arm was
hosen to provide the study with 80% power for distinguishing
etween an event rate of 50% and 35% in the 2 arms, allowing
2-sided type I error rate of 5%, a crossover rate of 2.5%, and
further 10% lost to follow-up (21).
Primary analyses were conducted on an intention-to-treat
asis. One interim analysis was performed once 50% of the
atients had accrued, to determine whether the PET-
irected approach was beneficial or hazardous. O’Brien-
leming group (25) sequential stopping rules were used to
aintain an overall significance level of 0.05. Significance
oundaries were symmetrical, with alpha  0.019 for the
nterim analysis and alpha  0.043 for the final analysis.
Baseline characteristics of patients in the 2 arms were
ompared by using the t test for continuous variables and
hi-square test for categorical variables. An uncorrected
hi-square test was used to compare the proportion of events
n each study arm. A logistic regression procedure was
mployed to adjust the comparison of these event rates with
ignificant covariates that predicted outcome.
Categorical variables, including the components of the
omposite event, were analyzed by using an uncorrected
hi-square test followed by multiple logistic regression
nalysis. Survival analyses were used to compare event-free
urvival. Kaplan-Meier survival curves were compared with
he log-rank test. Proportional hazards methods were used
s appropriate.
To address secondary objectives, intention-to-treat anal-
sis was only undertaken for subgroups where there had
een stratification before randomization or where the pa-
ameter significantly impacted the effect of FDG PET-
ssisted management or standard care on the outcome. This
as the case for patients with and without recent angiog-
aphy for which there was a priori stratification before
andomization.
Because a patient’s course might not adhere to the
ecommendations of the PET imaging, an additional post
oc analysis was conducted to determine the outcome in the
deal circumstances when decisions adhered to PET recom-
endations. Thus, an “adherence” group was defined
mong patients in the PET arm. This adherence group
ncluded patients: 1) who underwent PET; 2) who had
oderate or high amounts of viability and adhered to the
ET recommendations by undergoing protocol revascular-
zation or revascularization work-up; and 3) who had low
mounts of viability so did not undergo protocol revascu-
arization or revascularization work-up or underwent aneu-
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FDG PET-Assisted Management (The PARR-2 Study) November 13, 2007:2002–12ysm resection because of a large scar. Patients who had
vents before PET imaging or before revascularization or
evascularization work-up were excluded from this post hoc
utcome analysis, as these events may have partly driven
evascularization or revascularization work-up. Inclusion of
hese patients would not allow determination of the benefit
f following the PET recommendations. The “adherence to
ET” recommendations group was compared with patients
n the standard care arm.
Finally, PET might add benefit after other stress and
iability testing. Thus, in a post hoc analysis, patients with
revious stress or viability imaging testing enrolled in the
ET arm were compared with the standard arm with or
ithout at least 1 test performed before or after random-
zation that could be used to assist with decision-making.
esults
ine sites randomized 430 patients. Coronary artery disease
riteria listed previous angiography (remote or recent)
nd/or previous revascularization as 1 of the criteria in 349
atients. In 25 patients, a history of MI, verified by chart
eview, was the single criterion listed. In 29 patients,
ositive stress perfusion imaging was the single criterion
isted. In 28 patients, both MI and positive imaging were
isted. Patients were randomized to FDG PET-assisted
anagement (218 patients) or standard care (212 patients).
he baseline characteristics were similar (Table 1).
Eighteen patients (9 PET arm, 9 standard arm) with LV
ysfunction who initially seemed to meet inclusion criteria
ere found to have an EF 0.35 on the RVG done at the
ime of enrollment. Although these patients were random-
zed inappropriately, they were followed and included in the
ntention-to-treat analysis. Additional patients were enrolled
o ensure that a sufficient number of patients met all inclusion
riteria. Hence, 430 patients were enrolled in the study.
In the PET arm, 207 patients underwent PET imaging.
leven did not. In the standard arm, 5 underwent PET
maging (after another initial test) and 207 did not. The
ET image quality was considered poor in 4 cases (1.9%),
wing to poor FDG uptake, and fair in 16 cases (7.7%).
Characteristics of Patients at Entry
Table 1 Characteristics of Patients at Entry
Age, mean (SD)
Gender, male (%)
Baseline EF, mean (SD)
Diabetes, n (%)
Prior infarction, n (%)
Angiography in previous 6 months, n (%)
Prior CABG, n (%)
Angina (CCS class II–IV), n (%)
Dyspnea (NYHA functional class II–IV), n (%)
Creatinine (mol/l), mean (SD)CABG coronary artery bypass graft; CCS Canadian Cardiovascular Society
York Heart Association; PET  positron emission tomography.hen image quality was poor, the perfusion data were used
n combination with the best interpretation possible from
he FDG data. The attending physician was informed of the
oor image quality.
In the PET arm, 58, 103, and 46 patients were consid-
red to have high, moderate, and low amounts of viability,
espectively; 104 (47.7% of group) underwent protocol
evascularization. Of these, 71 (68%) underwent CABG.
ive patients underwent late revascularization (109 total
evascularizations).
In the standard arm, 74 (34.9% of group, p  0.007
ompared with PET) underwent protocol revascularization.
f these, 55 underwent CABG (74%; p  NS compared
ith PET). Nine patients underwent late revascularization
83 total revascularizations). The effect of PET-assisted
anagement was not modified by having or not having
evascularization (p  NS for interaction).
oronary anatomy. Among the patients with available
ngiography data for review (recent pre-randomization
ngiography or post-randomization), 268 of 300 (89.3%)
ad 2-vessel, 3-vessel, or left main disease with 50%
tenoses: 148 of 165 (89.7%) patients in the PET arm
ompared with 120 of 135 (88.9%) patients in the standard
rm (p  NS). Distal disease of 50% in at least 2 distal
egments was noted in 51 (30.9%) PET arm patients and 47
34.8%) standard arm patients (p  NS). Distal disease in
he left anterior descending coronary artery was noted in 28
17%) PET arm patients with angiography and 23 (17%)
tandard arm patients with angiography (p  NS). A small
umber of patients (10, 3.3%) did not have a significant
tenosis at the time of the post-randomization angiogram in
pite of meeting 1 or more inclusion criteria (6 in the PET
rm, and 4 in the standard arm). Because our goal was to
etermine the added value of FDG PET among patients
eing assessed for viability and these patients had been
eferred for such and because these patients met the inclu-
ion criteria set and had been randomized, these patients
ere included in the primary intention-to-treat analysis.
ardiovascular events. One-year follow-up data was com-
leted for 209 patients (96% of randomized) in the PET
ET-Assisted Management
(n  218)
Standard Care
(n  212)
63.0 (10.0) 62.0 (10.3)
184 (84.4) 179 (84.4)
27.0 (7.4) 26.1 (8.0)
90 (41.3) 77 (36.3)
176 (80.7) 170 (80.2)
115 (52.8) 109 (51.4)
46 (21.1) 34 (16.0)
101 (46.3) 97 (45.8)
175 (80.3) 177 (83.5)
110 (62) 106 (38)FDG P; EF ejection fraction; FDG F-18-fluorodeoxyglucose; NYHA New
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November 13, 2007:2002–12 FDG PET-Assisted Management (The PARR-2 Study)rm and 209 patients (99% of randomized) in the standard
rm (Fig. 2). First events were cardiac death (n  29), MI
n  13), and cardiac hospital stay (n  94). Two patients
ere censored at the time of cardiac transplant, which
ccurred before any cardiac event. Thus, 136 patients
xperienced an event of interest; 45 patients had cardiac
eaths.
The cumulative proportion of patients who experienced
he composite event was 30% in the PET arm and 36% in
he standard arm (relative risk 0.82, 95% CI 0.59 to 1.14, p
0.16). Two events in the PET arm occurred before PET
maging.
For all patients, the hazard ratio (HR) for the composite
vent, in the PET arm compared with the standard care
rm, was 0.78 (95% CI 0.58 to 1.1, p  0.15) (Fig. 3). For
atients with EF 0.35 on RVG at the time of enrollment
nd after excluding those identified as not having significant
oronary stenosis, the HR was 0.77 (95% CI 0.55 to 1.09,
 0.14).
ardiac death. There were 19 cardiac deaths in the PET
rm and 26 in the standard arm. By intention-to-treat
nalysis, the HR for cardiac death was 0.72 (95% CI 0.40 to
.3, p  0.25) (Fig. 4). Further analysis was undertaken for
he subgroups with and without prior angiography, because
Sites
N=9
Consented
N=430
Randomized
PET-Guided Therapy Standard Care
N=218 N=212
Drop-out Followed Drop-out Followed
N=9 N=209 N=3 N=209
Non-CardiacNon-Cardiac
Available AvailableDeathDeath
N=205 N=207N=2 N=2
Transplant
N=2*
Event No EventEvent No Event
N=75N=61 N=144 N=132
Figure 2 Flow Diagram of Recruitment, Randomization,
Dropouts, Noncardiac Death, and Events at 1 Year*
*Two patients had cardiac transplant before any other cardiac event and were
censored at the time of transplantation. PET  positron emission tomography.his was defined a priori and there was stratification beforeandomization. There were no differences between PET
nd standard arms for those who had recent angiography
relative risk  1.29; 95% CI 0.57 to 2.95; p  0.69).
Among 206 patients without recent angiography, 1 had a
oncardiac death and 4 dropped out, leaving 201 patients.
here was a significant reduction in cardiac deaths in the
ET arm compared with standard care: 7 of 99 (7.1%)
ersus 17 of 102 (16.7%) (relative risk  0.42, 95% CI 0.18
o 0.98; p 0.036). The HR for the PET arm was 0.4 (95%
I 0.17 to 0.96; p  0.035) (Fig. 5). There were no
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Days
Figure 3 “Survival Curves” (on the Basis of Time to
First Occurring Outcome of the Composite Event)
Mantel-Haenszel (log-rank) test for differences between 2 survival curves; chi-
square  2.1, hazard ratio  0.78, 95% CI 0.58 to 1.1, p  0.15. PET 
positron emission tomography.
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Figure 4 “Survival” Curves (on the Basis of
Time to Cardiac Death) for All Subjects
Mantel-Haenszel (log-rank) test for differences between 2 survival curves; chi-
square  1.3, hazard ratio  0.72, 95% CI 0.4 to 1.3, p  0.25. PET 
positron emission tomography.
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tandard care arms.
Compared with patients with recent angiography, those
ithout had lower EF (p 0.007), had worse renal function
p  0.002), had more previous CABG (p  0.0001), were
lder (p 0.053), and tended to have more previous MIs (p
0.06). Thus, patients without recent angiography repre-
ented a sicker population (Table 2).
dherence to PET recommendations. Among the 218
atients randomized to the PET arm, 207 had PET
maging. For those who underwent PET imaging, 156 of
07 (75.4%) adhered to the PET recommendation. Table 3
escribes why patients with high or moderate amounts of
iability on PET did not undergo revascularization workup
r revascularization. Table 4 tabulates the reasons why
atients with low amounts of viable myocardium underwent
evascularization or work-up. Among the patients with low
iability: 1) 3 had aneurysm resection; these patients were
onsidered to have adhered to PET recommendations,
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Figure 5 “Survival Curves” (on the Basis of Time to Cardiac
Death) for Patients Without Recent Angiography
Mantel-Haenszel (log-rank) test for differences between 2 survival curves; chi-
square  4.5, hazard ratio  0.4, 95% CI 0.17 to 0.96, p  0.035. PET 
positron emission tomography.
haracteristics of Patients With and Without Recent Angiography
Table 2 Characteristics of Patients With and Without Recent A
Patients Wit
(
Mean age, yrs (SD) 6
Gender, male (%)
Baseline EF, mean (SD) 2
Diabetes, n (%)
Prior infarction, n (%)
Prior CABG, n (%)
Angina (CCS class II–IV), n (%)
Dyspnea (NYHA functional class II–IV), n (%)
Creatinine (mol/l), mean (SD)p  0.05;  0.08. †p  0.01. ‡p  0.0001.
Abbreviations as in Table 1.ecause scar had been identified and appropriate treatment
nsued; 2) 8 patients did not adhere to PET recommenda-
ions: 5 had revascularization, 1 had attempted revascular-
zation that was not successful, and 2 had revascularization
ork-up without revascularization (Table 4).
Thirty patients with high or moderate amounts of viabil-
ty underwent revascularization work-up without getting
evascularized. Reasons for these patients not undergoing
evascularization are listed in Table 5.
Figure 6A shows the distribution of patients who adhered
o recommendations on the basis of the amount of viable
yocardium. Adherence rates were 86.2%, 66.0%, and
2.6%, respectively, for high, moderate, and low amounts of
iability (p  0.05 moderate vs. others). Figure 6B shows
he distribution of patients who underwent protocol revas-
ularization or revascularization work-up in each group:
6.2%, 66.0%, and 23.9% for high, moderate, and low
iability, respectively (p  0.01).
In the post hoc analysis, which compared the “adherence
o PET” subgroup with standard care, previous CABG had
significant association with the outcome (HR  2.1; p 
.0003). Adjusting for this, the HR for the “adherence to
ET” subgroup was 0.62 (95% CI 0.42 to 0.93, p  0.019)
Fig. 7).
ther testing. In the PET arm, 86 patients had a stress or
iability imaging test in the 3 months before randomization.
graphy
nt Angiography
24)
Patients Without Recent Angiography
(n  206)
0.2) 63.5 (10.1)*
5.3) 172 (83.5)
.7) 25.5 (7.6)†
1.5) 74 (35.9)
7.2) 173 (84.0)*
.9) 69 (33.5)‡
8.2) 90 (43.7)
1.3) 169 (82.0)
9) 112 (42)†
easons for “No Revascularization” orNo Revascularization Work-Up” i Patients Withigh r Medium Viability
Table 3
Reasons for “No Revascularization” or
“No Revascularization Work-Up” in Patients With
High or Medium Viability
Patient refusal/withdrawal 4 (1.9%)
Renal failure 9 (4.3%)
Multiple other comorbidities (age, COPD, vasculopathy) 5 (2.4%)
Cardiac event (death) 2 (0.5%)
Cardiac event (hospitalized, CHF, arrest) 1 (1.0%)
Symptoms stabilized 13 (6.2%)
Scar on other prior test 2 (1.0%)
Unknown (could not be determined) 7 (3.4%)
Total patients among 207 patients with PET* 43 (25.7%)
Does not include 11 patients who did not have positron emission tomography (PET) imaging in the
ET arm.
CHF  congestive heart failure; COPD  chronic obstructive pulmonary disease.ngio
h Rece
n  2
1.6 (1
191 (8
7.5 (7
93 (4
173 (7
11 (4
108 (4
182 (8
104 (5
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November 13, 2007:2002–12 FDG PET-Assisted Management (The PARR-2 Study)n the standard arm, 93 patients had stress or viability
esting in the 3 months before randomization and 77 had
esting after randomization. A total of 138 patients had at
east 1 stress or viability imaging test in the standard arm.
or patients in the PET arm with prior stress or viability
esting, there was a significant benefit compared with: 1)
hose in the standard arm with testing: unadjusted HR 
.5 (95% CI 0.28 to 0.88; p  0.017) and adjusted HR 
.46 (95% CI 0.25 to 0.81; p  0.007) (after adjustment for
rior CABG [HR  1.9; p  0.04], which was a con-
ounder); 2) patients in the standard arm without recent
esting: HR  0.44 (95% CI 0.24 to 0.82; p  0.009; no
onfounders); and 3) patients in the PET arm without prior
esting: HR  0.48 (95% CI 0.27 to 0.86; p  0.013; no
onfounders).
iscussion
o our knowledge, the PARR (PET and Recovery Follow-
ng Revascularization)-2 study is the largest randomized
tudy to evaluate whether FDG PET-assisted management
as a beneficial effect on clinical outcomes and is the first
andomized trial to evaluate viability imaging in patients
ith severe LV dysfunction.
Although patients in the FDG PET-assisted manage-
ent arm tended to have fewer cardiovascular events within
year, this difference was not significant. Thus the findings
or the primary outcome must be considered inconclusive.
egarding secondary outcomes, by intention-to-treat, pa-
ients without recent angiography in the FDG PET-
ssisted management arm had a statistically significant
eduction in cardiac death.
From post hoc analyses, under the ideal circumstances
hen there is adherence to PET recommendations, a
easons for “Revascularization” or “Revascularizationork-Up” in Patients With Low Amounts of Vi bility
Table 4 Reasons for “Revascularization” or “RevascularizationWork-Up” in Patients With Low Amounts of Viability
Recurrent or persistent symptoms 5 (2.4%)
LMCA disease 1 (0.5%)
TVR for region of viability 1 (0.5%)
Unknown 1 (0.5%)
Total patients among 207 patients with PET* 8 (3.9%)
oes not include 3 patients with aneurysm procedures. *Does not include 11 patients who did not
ave positron emission tomography (PET) imaging in the PET arm.
LMCA  left main coronary artery; TVR  target vessel revascularization.
easons for Not Undergoing Revascularization in0 Patients Wi h High or Mod rate Vi bility Whonderw “Revascularizati n Work-Up”
Table 5
Reasons for Not Undergoing Revascularization in
30 Patients With High or Moderate Viability Who
Underwent “Revascularization Work-Up”
Diffuse disease, anatomy not amenable to revascularization 12 (5.8%)
Patent grafts 6 (2.9%)
No major flow limiting stenosis 6 (2.9%)
Symptoms stabilized 2 (1.0%)
Unknown 4 (1.9%)
Total patients among 207 patients with PET* 30 (13.4%)t
Does not include 11 patients who did not have positron emission tomography (PET) imaging in the
ET arm.ignificant reduction in adverse outcomes was observed. In
ddition, patients in the PET arm with recent stress or
iability testing had better outcome than those with testing
n the standard arm and those without testing in either arm.
xisting published reports and ongoing trials. Observa-
ional studies have consistently demonstrated that patients
ith viable myocardium on FDG PET are at high risk for
ardiac death or events if they do not undergo timely
evascularization (14–20,26–28). However, many of these
tudies are small and have inherent biases in patient selec-
ion that might influence outcome. The current trial also has
ome potential bias in patient selection and referral, because
he management course was not absolutely mandated by the
est. However, this was also true for the standard care arm.
lthough it is not possible to prove that such clinical bias is
alanced between groups, randomization is expected to
alance this as much as possible.
One previous study randomized patients to PET versus
Figure 6 Rates of Adherence, Revascularization,
and Revascularization Work-Up
(A) Rates of adherence to positron emission tomography recommendations for
revascularization or revascularization work-up (*p  0.05 for moderate vs. oth-
ers). (B) Rates of revascularization (solid bars); revascularization work-up with-
out revascularization (hatched bars), and no revascularization (open bars).
Rates of revascularization  revascularization were different between groups
(*p  0.01 vs. other amounts of viability).echnetium-99m sestamibi single-photon emission com-
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FDG PET-Assisted Management (The PARR-2 Study) November 13, 2007:2002–12uted tomography-guided management (29). This study
id not show a significant difference in outcome. However,
nly 36 of 103 patients had severe LV dysfunction. Con-
idering the lower risk of such patients and the small sample
ize, the study was likely underpowered.
The ongoing STICH (Surgical Treatment for Ischemic
eart Failure) trial (30) compares revascularization to
edical therapy to surgical reconstruction of the LV (9).
agnetic resonance imaging (MRI) is being used for
iability imaging but is not used to direct therapy. Viability
esting is permitted to select patients suitable for random-
zation, but is not used to direct therapy after randomiza-
ion. Although the trial will yield vital data regarding
urgical therapies in patients with severe LV dysfunction
EF 35%), data on viability imaging will be observational
nd, hence, might be unable to provide an unbiased estimate
f the effects of imaging on decision-making or outcome. In
he ongoing HEART (Heart Failure Revascularisation
rial) study (31), patients with EF 35% and large
mounts of jeopardized myocardium on perfusion imaging
r dobutamine echocardiography will be randomized to
evascularization or medical therapy. Patients might also
ndergo PET or MRI. As with the STICH trial, useful data
n the role of revascularization will arise. However, data on
he role of viability imaging and decision-making might be
ncomplete, because patients with moderate or lesser
mounts of hibernation and ischemia are not included and
he use of PET or MRI is ad hoc rather than randomized.
urrent findings and clinical relevance. Although the
ower event rate in the PET-assisted management arm
ould seem supportive of findings from previous observa-
ional studies, the results did not reach statistical signifi-
ance, so a definitive conclusion cannot be drawn regarding
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ADHERE arm
Figure 7 “Survival Curves” (on the Basis of Time to First
Occurring Outcome Out of the Composite Event)
The positron emission tomography adherence group versus standard care arm.
Mantel-Haenszel (log-rank) Test for differences between 2 survival curves;
adjusted hazard ratio  0.62, 95% CI 0.42 to 0.93, p  0.019.he composite end point. dThe observed event rates of 36% in the standard arm and
0% in the PET arm were lower than projected. This
educed our ability to detect a significant difference.
onger-term follow-up is underway and would be expected
o provide additional power. The demographic data were
imilar to many previous viability studies that enrolled
atients with severe LV dysfunction (14–20). Thus, the
ower-than-expected event rates might reflect improve-
ents in medical, device, and revascularization therapy
1–6,8,9).
The randomization was pre-stratified by whether the
atient had angiography within the preceding 6 months. In
he patients without angiography in the preceding 6
onths, a lower mortality was demonstrated for FDG
ET-assisted management. At first glance this might seem
ifficult to understand. However, this group was sicker than
hose with recent angiography (older with more previous
ABG and MIs, lower EF, and worse renal function).
atients with previous bypass are already known to have
ignificant disease that is likely to be more diffuse and less
menable to repeat revascularization. Such patients are also
t increased risk for redo surgery or intervention (32). It is
uch patients where decisions for revascularization become
ven more critical. Thus, it is not surprising that a technique
hat can optimize patient selection of those more or less
ikely to benefit might have a mortality benefit in this
opulation.
Post hoc analysis suggests that the group of patients in
he PET arm who had already had some form of stress or
iability testing had a significant benefit. This suggests that
diagnostic algorithm that includes PET after initial testing
ight provide a clinical benefit in this patient population.
nterpretation here must be made with caution, because the
tudy was not designed to compare specific types of alternate
esting and because this was a post hoc analysis. Further
erification of this finding in other clinical trials is required.
tudy limitations and other considerations. Clinical
ecision-making is often complex for patients with severe
V dysfunction. In previous observational studies, between
0% and 50% (mean 42%) of patients who were classified as
aving viable myocardium did not undergo revascularization
14–20). In the current study, 24.6% of patients did not
dhere to the recommendations that were based on the PET
maging data. This likely reduced our ability to detect a
ifference in the primary outcome analysis. The extent of
iability is 1 of several factors that might influence a
hysician’s decision for a given management course and thus
mpact subsequent outcome (33). Physicians must balance
he best available information on the likelihood of recovery
ersus patient risk often due to other comorbidities. That
DG PET data do impact decision-making is supported by
he data in Figure 6, showing that the likelihood of
evascularization or revascularization work-up depended on
he amount of viable myocardium. The current data also
upport that there are often other factors that complicate
ecisions and influence outcomes (33).
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November 13, 2007:2002–12 FDG PET-Assisted Management (The PARR-2 Study)The interpretation of PET imaging can be complex and
ust consider extent of scar, mismatch, total viability, and
ombinations thereof. It is possible that our simplified ap-
roach of dividing patients into high-, moderate-, and low-
ikelihood for recovery also contributed to the lack of adher-
nce. This effect was likely small, more likely affecting those
atients at or near cut points. This again reflects the complexity
f decision-making in patients with severe LV dysfunction.
To address the impact of adherence, we did a post hoc
nalysis comparing outcomes among patients who adhered
o the PET recommendations versus standard care. These
esults showed a significant reduction in events under the
deal circumstances of when there is adherence to PET
ecommendations. Because the control group was not sub-
ect to this screening, potential bias in this post hoc analysis
ight exist. Adjustment was made for the lone confounder
ffecting outcome, namely previous CABG. Thus the
roups were relatively balanced. Although this post hoc
nalysis must be interpreted with caution, it does indicate
he importance of following PET imaging recommenda-
ions and the potential benefits that might ensue.
This study did not include follow-up perfusion or angio-
raphic data to confirm the adequacy of revascularization.
lthough there seems to be no reason to suspect that the
uccess rate of revascularization was different among those
n each group who were revascularized, this cannot be
onfirmed or refuted. It seems unlikely to us that this
mpacted the outcome findings observed.
The current study demonstrates the difficulties in design-
ng randomized trials to evaluate clinical outcomes for
iagnostic tests and diagnostic strategies, as opposed to
pecific therapies. Not only do randomized clinical trials for
iagnostic strategies depend on the test accuracy but also on
he willingness of physicians and patients to follow the
ecommended treatment and the effectiveness of the treat-
ent itself. Future trials of diagnostic strategies should
onsider these issues in their design.
THER MODALITIES. The study does not compare PET
ith specific alternative imaging modalities that often vary
epending on site expertise and technique availability. Such
comparison was not the aim of the PARR-2 trial. Rather
he primary aim was to determine whether a FDG PET-
ssisted management approach improves clinical outcomes
ompared with standard care.
DVANCES IN IMAGING. The lessons learned from the
ARR-2 trial might provide a framework to evaluate new
ybrid PET/computed tomography devices (34) and other
dvanced viability imaging modalities, such as MRI. Mag-
etic resonance imaging, with its excellent anatomical res-
lution, is emerging as a useful tool for evaluating viability
nd predicting wall motion recovery. Whether this resolu-
ion advantage would translate into outcome benefit is not
nown. Few outcome studies have evaluated MRI in patient
opulations with severe LV dysfunction (20). Contrast- dnhanced MRI might carry a potential risk for nephrogenic
ystemic fibrosis that might be as high as 1.5% in patients
ith reduced creatinine clearance (35). Impaired renal
unction is very common in the patient population with
evere LV dysfunction, including the current study where
4% of patients had reduced creatinine clearance rates. This,
long with the paucity of outcome data, suggests that FDG
ET remains an important advanced viability imaging
odality in severe LV dysfunction.
onclusions
he urgent need for randomized controlled studies applying
maging technology that evaluate outcomes has recently
een highlighted (36). The PARR-2 study represents such
trial. It is, to our knowledge, the first large randomized
rial to evaluate whether a strategy that includes FDG PET
o assist in directing management is effective in patients
ith severe LV dysfunction.
Although the event rate in the FDG PET arm was less than
he standard arm, the overall study must be considered incon-
lusive, because there was no statistically significant difference
or the primary outcome measure. However, there are a
umber of important findings from the PARR-2 study.
First, FDG PET did have important impact on manage-
ent decisions in many patients, as evidenced by the
ifferent rates of revascularization and work-up relative to
he extent of viability. Second, as with previous observa-
ional studies, there was a large proportion (approximately
5%) of patients who did not adhere to the PET recom-
endations in spite of moderate and even high amounts of
iable myocardium. This implies that, for clinicians making
ecisions, the evidence for revascularization benefit is not
onvincing enough to warrant the potential or perceived
dded risk in some patients. Ongoing randomized trials will
ddress this question further (30,31). Third, when patients
ho adhered to the PET recommendations were consid-
red, there was a significant benefit for FDG PET, indi-
ating the positive impact that FDG PET imaging might
ave under the ideal circumstances when viability data are
onsidered and recommendations are followed. Fourth, an
utcome benefit for PET-assisted management was ob-
erved when it was used in addition to a preceding test. This
arrants further study. Finally, in a pre-defined intention-
o-treat analysis, there was a patient population, without
ecent angiography, who represent the sickest group of
atients, where FDG PET-assisted management yields a
ignificant mortality benefit.
In conclusion, the data suggest that many patients with
evere LV dysfunction and suspected CAD might not
lways benefit from FDG PET imaging. However, there is
otential value for FDG PET, particularly in a high-risk
atient population where decisions for therapy are most
ifficult. When patients adhere to FDG PET recommen-
ations, a reduction in events might be realized.
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